

13 November 2025

**Futura Medical plc**  
("Futura", "the Group" or the "Company")  
**Posting of Circular and Notice of General Meeting**

Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that further to the announcement on 13 November 2025 relating to its fundraise of £2.75 million, it has despatched the Circular and Notice of General Meeting to Shareholders.

The Circular and Notice of General Meeting is available on the Company's website: [Corporate documentation - Futura Medical](#)

The Directors confirm they are to hold a General Meeting of the Company at the Company's registered office at Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG at 10 a.m. on 2 December 2025.

The results of voting on all resolutions at the General Meeting will be announced via RNS, and the full results of the voting will be published on the Company's website after the conclusion of the General Meeting.

**Contacts:**

<b>Futura Medical plc</b>	Alex Duggan <i>Interim Chief Executive Officer</i> Angela Hildreth <i>Finance Director and COO</i>	<a href="mailto:investor.relations@futuramedical.com">investor.relations@futuramedical.com</a> +44 (0)1483 685 670 <a href="http://www.futuramedical.com">www.futuramedical.com</a>
<b>Panmure Liberum</b> Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	+44 (0)20 3100 2000
<b>Turner Pope</b> <b>Investments (TPI)</b> <b>Ltd - Broker</b>	James Pope, Andrew Thacker	+44 (0) 20 3657 0050
<b>Alma Strategic</b> <b>Communications</b>	Rebecca Sanders-Hewett Sam Modlin Emma Thompson	+44 (0)20 3405 0205 <a href="mailto:futura@almastrategic.com">futura@almastrategic.com</a>

**Notes to Editors:**

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOGFLFVRLVLVLIE